Manufacturing peptides as active pharmaceutical ingredients

Future Medicinal Chemistry

Volumn 1, Issue 2, 2009, Pages 361-377

  Zompra, Aikaterini A ^a   Galanis, Athanassios S ^a   Werbitzky, Oleg ^b   Albericio, Fernando ^c  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b LONZA AG   (Switzerland)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTICOAGULANT AGENT; CYCLOSPORIN A; ENFUVIRTIDE; EXENDIN 4; HIRULOG; IPRIVASK; OMEGA CONOTOXIN MVIIA; PARATHYROID HORMONE[1-34]; PRAMLINTIDE; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG DECOMPOSITION; DRUG INDUSTRY; DRUG ISOLATION; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW;

FERMENTATION; GENETIC ENGINEERING; PEPTIDE BIOSYNTHESIS; PEPTIDES; PHARMACEUTICAL PREPARATIONS;

EID: 70350323495     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.23     Document Type: Review

References (53)

1. Kent S. Obituary: Bruce Merrifield (1921-2006). Inventor of solid-phase peptide synthesis. Nature 441, 824 (2006).
2. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149-2154 (1963).
3. Bruckdorfer T, Marder O, Albericio F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr. Pharm. Biotech. 5, 29-43 (2004).
4. Pichereau C, Allary C. Therapeutic peptides under the spotlight. Eur. Biopharm. Rev. Winter issue, 88-93 (2005).
5. Sehgal A. New Applications In Discovery, Manufacturing, and Therapeutics: Peptides 2006, Research and Markets. D&MD Publications, MA, USA (2006).
6. Ayoub M, Scheidegger D. Peptide drugs, overcoming the challenges, a growing business. Chem. Today. 24, 46-48 (2006).
7. Bray BL. Innovation: large-scale manufacture of peptide therapeutics by chemical synthesis. Nature Rev. Drug Discovery. 2, 587-593 (2003).
8. Werbitzky O, Brichard MH. Technology for peptide large scale manufacturing: technical, quality, and regulatory challenges. Presented at: TIDES Conference. Taipei, Taiwan, 20 May 2008.
9. Tam JP, Lu YA. Coupling difficulty associated with interchain clustering and phase transition in solid phase peptide synthesis. J. Am. Chem. Soc. 117, 12058-12063 (1995).
10. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers 55, 227-250 (2000).
11. Lloyd-Williams P, Albericio F, Giralt E. Convergent solid-phase peptide synthesis. Tetrahedron 49, 11065-11133 (1993).
12. Du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc. 75, 4879-4880 (1953).
13. Werbitzky O, Oehlers D. Manufacturing peptide APIs in the scope of upcoming new challenges higher complexity and industrialization. Chem. Today 26, 26-28 (2008).
14. Miranda LP, Alewood PF. Challenges for protein chemical synthesis in the 21st century: bridging genomics and proteomics. Biopolymers 55, 217-226 (2000).
15. Garcia Martin F, Albericio F. Solid supports for the synthesis of peptides. From the first resin used to the most sophisticated in the market. Chem. Today 26, 29-34 (2008).
16. Albericio F, Chinchilla R, Dodsworth DJ, Najera C. New trends in peptide coupling reagents. Org. Prep. Proc. Int. 33, 203-303 (2001).
17. Albericio F. Developments in peptide and amide synthesis. Curr. Opin. Chem. Biol. 8, 211-221 (2004).
18. Carpino LA, Han GY. The 9-fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group. J. Am. Chem. Soc. 92, 5748-5749 (1970).
19. Kimmerlin T, Seebach D. 100 years of peptide synthesis: ligation methods for peptide and protein synthesis with applications to b-peptide assemblies. J. Pep. Res. 65, 229-260 (2005).
20. García-Martín F, Quintanar-Audelo M, García-Ramos Y et al. ChemMatrix, a poly(ethylene glycol)-based support for the solid-phase synthesis of complex peptides. J. Comb. Chem. 8, 213-220 (2006).
21. Albericio F, van Abel R, Barany G. Solid-phase synthesis of peptides with C-terminal asparagine or glutamine. Int. J. Peptide Protein Res. 35, 284-286 (1990).
22. Mutter M, Nefzi A, Sato T, Sun X, Wahl F, Wuhr T. Pseudo-prolines (y Pro) for accessing inaccessible peptides. Peptide Res. 8, 145-153 (1995).
23. García-Martín F, White P, Steinauer R, Côté S, Tulla-Puche J, Albericio F. The synergy of ChemMatrix resin and pseudoproline building blocks renders Rantes, a complex aggregated chemokine. Biopolymers 84, 566-575 (2006).
24. Vázquez J, Qushair G, Albericio F. Qualitative colorimetric tests for solid phase synthesis. In: Methods in Enzymology (Volume 369). Morales G (Ed.). Academic Press, CA, USA 21-35 (2003).
25. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696-1705 (2006).
26. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab. 8, 436-447 (2006).
27. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 114, 417-423 (2006).
28. Madsen K, Knudsen LB, Agersoe H et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 50, 6126-6132 (2007).
29. Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin. Pharmacother. 9, 1575-1583 (2008).
30. Bodanszky M. Peptide Chemistry: a Practical Textbook. Springer-Verlag, Berlin, Germany (1988).
31. Sieber P. A new acid-labile anchor group for the solid-phase synthesis of C-terminal peptide amides by the Fmoc method. Tetrahedron Lett. 28, 2107-2110 (1987).
32. Barlos K, Gatos D, Kallitsis J et al. Darstellung geshutzter peptid-fragmente unter einsatz substituierter triphenylmethylharze. Tetrahedron Lett. 30, 3943-3946 (1989).
33. Barlos K, Gatos D, Kapolos S, Papaphotiu G, Schäfer W, Wenqing Y. Veresterung von partiell geschutzten peptid-fragmenten mit harzen. Einsatz von 2-chlortritylchlorid zur synthese von Leu15-gastrin I. Tetrahedron Lett. 30, 3947-3950 (1989).
34. Eipper BA, Milgram SL, Husten EJ, Yun HY, Mains RE. Peptidylglycine a-amidating monooxygenase: a multifunctional protein with catalytic, processing, and routing domains. Protein Sci. 2, 489-497 (1993).
35. Bradbury AF, Finnie MDA, Smyth DG. Mechanism of C-terminal amide formation by pituitary enzymes. Nature 298, 686-688 (1982).
36. Katopodis AG, Ping D, May SW. A novel enzyme from bovine neurointermediate pituitary catalyzes dealkylation of a-hydroxyglycine derivatives, thereby functioning sequentially with peptidylglycine a-amidating monooxygenase in peptide amidation. Biochemistry 29, 6115-6120 (1990).
37. Dawson PE, Muir TW, Clark-Lewis I, Kent SB. Synthesis of proteins by native chemical ligation. Science 266, 776-779 (1994).
38. Dawson PE, Kent SB. Synthesis of native proteins by chemical ligation. Annu. Rev. Biochem. 69, 923-960 (2000).
39. Macmillan D. Evolving strategies for protein synthesis converge on native chemical ligation. Angew. Chem. Int. Ed. 45, 7668-7672 (2006).
40. Gill I, López-Fandiño R, Jorba X, Vulfson EN. Biologically active peptides and enzymatic approaches to their production. Enzyme Microb. Technol. 18, 163-183 (1996).
41. Kumar D, Bhalla TC. Microbial proteases in peptide synthesis: approaches and applications. Appl. Microbiol. Biotechnol. 68, 726-736 (2005).
42. Garoff H. Using recombinant DNA techniques to study protein targeting in the eucaryotic cell. Ann. Rev. Cell Biol. 1, 403-445 (1985).
43. Wallace CJA. Protein Engineering by Semisynthesis. CRC Press, FL, USA (2000).
44. Lloyd-Williams P, Albericio F, Giralt E. Chemical Approaches to the Synthesis of Peptides and Proteins. CRC Press, FL, USA (1997).
45. Sallam LA, El-Refai AM, Hamdi AH, El-Minofi HA, Abd-Elsalam IS. Studies on the application of immobilization technique for the production of cyclosporin A by a local strain of Aspergillus terreus. J. Gen. Appl. Microbiol. 51, 143-149 (2005).
46. Agathos SN, Madhosingh C, Marshall JW, Lee J. The fungal production of cyclosporine. Ann. NY Acad. Sci. 506, 657-662 (1987).
47. Sekar C, Balaraman K. Optimization studies on the production of cyclosporin A by solid state fermentation. Biol. Eng. 18, 293-296 (1998).
48. Nisha AK, Meignanalakshmi S, Ramasamy K. Comparative effect of amino acids in the production of cyclosporin by solid and submerged fermentation. Biotechnology 7, 205-208 (2008).
49. Metha NM. Oral delivery and recombinant production of peptide hormones. Part II. Recombinant production of therapeutic peptides. BioPharm. Inter. July, 7-9 (2004).
50. Shuman HA, Silhavy TJ. The art and design of genetic screens: Escherichia coli. Nat. Rev. Genet. 4, 419-431 (2003).
51. Won JI, Barron AE. A new cloning method for the preparation of long repetitive polypeptides without a sequence requirement. Macromolecules 35, 8281-8287 (2002).
52. De Wit H. Presented at: TIDES Conference. Las Vegas, NV, USA, 25-29 April 2004.
53. Frost, Sullivan. Strategic Analysis of the Therapeutic Peptides Market in Europe. San Antonio, TX, USA (2004).